1. PCSK9 inhibitors and osteoporosis: mendelian randomization and meta-analysis
- Author
-
Ding-Qiang Chen, Wen-Bin Xu, Ke-Yi Xiao, Zhi-Qiang Que, Jin-Yi Feng, Nai-Kun Sun, Di-Xin Cai, and Gang Rui
- Subjects
Mendelian randomization ,Osteoporosis ,PCSK9 ,HMGCR ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent an effective strategy for reducing cardiovascular disease risk. Yet, PCSK9’s impact on osteoporosis remains unclear. Hence, we employed Mendelian randomization (MR) analysis for examining PCSK9 inhibitor effects on osteoporosis. Methods Single nucleotide polymorphisms (SNPs) for 3-hydroxy-3-methylglutaryl cofactor A reductase (HMGCR) and PCSK9 were gathered from available online databases for European pedigrees. Four osteoporosis-related genome-wide association studies (GWAS) data served as the main outcomes, and coronary artery disease (CAD) as a positive control for drug-targeted MR analyses. The results of MR analyses examined by sensitivity analyses were incorporated into a meta-analysis for examining causality between PCSK9 and HMGCR inhibitors and osteoporosis. Results The meta-analysis involving a total of 1,263,102 subjects, showed that PCSK9 inhibitors can increase osteoporosis risk (P
- Published
- 2024
- Full Text
- View/download PDF